Thanks for the info, Jason.
Interesting when you try to find Telik publications...... one get lots on TRAP, but nothing on the drug candidates. The latest publication is an assay for insulin in rat plasma.
Going through the S-1..... this is one of the most leveraged of business plans ever known to the sector. The question is..... regarding this excerpt......
We have retained rights for the worldwide commercialization of TLK286 and TLK199.......
is that a reflection of wisdom, or of a lack of interest by potential partners? Given the rate at which TRAP is leading to hits, I'm going to continue to look closely at the S-1 and at the company......
Cancer Detect Prev 2000;24(3):252-7
Immunohistochemical expression of glutathione transferase-pi in untreated primary non-small-cell lung cancer.
Arai T, Yasuda Y, Takaya T, Hayakawa K, Toshima S, Shibuya C, Kashiki Y, Yoshimi
N, Shibayama M
Department of Internal Medicine, Gihoku General Hospital, Gifu, Japan.
[Medline record in process]
Patients with unresectable non-small-cell lung cancer (NSCLC) usually have undergone
chemotherapy; however, such problems as resistance to chemotherapeutic agents occur during
the treatments. Recent studies have indicated that glutathione S-transferase-pi (GST-pi) may play
an important role in the resistance of cancer cells to alkylating agents, including cisplatin
compounds. We examined a possible relationship between immunohistochemical expression of
GST-pi and the response to cisplatin plus etoposide chemotherapy in patients with untreated and
unresectable primary NSCLC. Of the 89 patients, 50 (56.2%) were GST-pi-positive and 39
(43.8%) were GST-pi-negative. For the patients with negative GST-pi expression, the response
rate was 66.7% (26 of 39 patients). In the patients with positive GST-pi expression, the
response rate was 26% (13 of 50 patients). This difference was statistically significant (P =
.0019). The results suggest that GST-pi expression in NSCLC tissues is related to response to
cisplatin plus etoposide chemotherapy and may be useful as a predictor of chemotherapy
response. |
